NEW YORK, Sept. 14, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Company sponsored an industry symposium at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Munich, Germany—the largest international forum for minimally invasive image-guided therapy, with more than 5,600 interventional radiologists in attendance.
The event, held Tuesday, September 13th, was moderated by Dr. Riccardo Lencioni—Associate Professor of Radiology and Head of Diagnostic Imaging and Intervention in the Department of Liver Transplantation, Hepatology and Infectious Diseases of the University of Pisa, and featured presentations by three U.S. physicians with direct experience with chemosaturation from the Company's Phase 3 Trial:Jonathan Zager, MD — Associate Professor of Surgery in the Cutaneous Oncology and Sarcoma Departments at the Moffitt Cancer Center – Evolution, Concepts and Utility for Patients with Liver Cancer James R. Pingpank,MD — Division of Surgical Oncology at the University of Pittsburgh Medical Center and Principal Investigator on the phase 3 trial of chemosaturation via (PHP) device - Summary of Phase 3 Clinical Trial Results Fred Moeslein, MD —Assistant Professor of Diagnostic Radiology and Nuclear Medicine at the University of Maryland Medical Center - Practical Experience with Chemosaturation
Commenting on the announcement, Eamonn P. Hobbs, President & CEO of Delcath, said, "This session was an opportunity to present detailed information on the clinical evidence and conceptual framework for chemosaturation to a broad audience of EU-based interventional radiologists. Attendance at the session exceeded the room's capacity. We believe this level of participation—combined with the favorable respon